| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:50 UTC |
|---|
| Update Date | 2022-03-07 02:51:43 UTC |
|---|
| HMDB ID | HMDB0014739 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Linezolid |
|---|
| Description | Linezolid is only found in individuals that have used or taken this drug. It is a synthetic antibiotic, the first of the oxazolidinone class, used for the treatment of infections caused by multi-resistant bacteria including streptococcus and methicillin-resistant Staphylococcus aureus (MRSA). Linezolid is a synthetic antibacterial agent of the oxazolidinone class of antibiotics. It has in vitro activity against aerobic Gram positive bacteria, certain Gram negative bacteria and anaerobic microorganisms. It selectively inhibits bacterial protein synthesis through binding to sites on the bacterial ribosome and prevents the formation of a functional 70S-initiation complex. Specifically, linezolid binds to a site on the bacterial 23S ribosomal RNA of the 50S subunit and prevents the formation of a functional 70S initiation complex, which is an essential component of the bacterial translation process. The results of time-kill studies have shown linezolid to be bacteriostatic against enterococci and staphylococci. For streptococci, linezolid was found to be bactericidal for the majority of strains. Linezolid is also a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. |
|---|
| Structure | CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1 InChI=1S/C16H20FN3O4/c1-11(21)18-9-13-10-20(16(22)24-13)12-2-3-15(14(17)8-12)19-4-6-23-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| N-(((S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide | ChEBI | | Zyvox | Kegg | | N-((3-(3-Fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide | HMDB | | Linezolide | HMDB |
|
|---|
| Chemical Formula | C16H20FN3O4 |
|---|
| Average Molecular Weight | 337.3461 |
|---|
| Monoisotopic Molecular Weight | 337.143784348 |
|---|
| IUPAC Name | N-{[(5S)-3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide |
|---|
| Traditional Name | linezolid |
|---|
| CAS Registry Number | 165800-03-3 |
|---|
| SMILES | CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1 |
|---|
| InChI Identifier | InChI=1S/C16H20FN3O4/c1-11(21)18-9-13-10-20(16(22)24-13)12-2-3-15(14(17)8-12)19-4-6-23-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1 |
|---|
| InChI Key | TYZROVQLWOKYKF-ZDUSSCGKSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as phenylmorpholines. These are aromatic compounds containing a morpholine ring and a benzene ring linked to each other through a CC or a CN bond. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Oxazinanes |
|---|
| Sub Class | Morpholines |
|---|
| Direct Parent | Phenylmorpholines |
|---|
| Alternative Parents | |
|---|
| Substituents | - Phenylmorpholine
- Aniline or substituted anilines
- Tertiary aliphatic/aromatic amine
- Dialkylarylamine
- Fluorobenzene
- Halobenzene
- Aryl fluoride
- Aryl halide
- Monocyclic benzene moiety
- Oxazolidinone
- Benzenoid
- Oxazolidine
- Acetamide
- Carbamic acid ester
- Secondary carboxylic acid amide
- Tertiary amine
- Amino acid or derivatives
- Carboxamide group
- Carbonic acid derivative
- Azacycle
- Oxacycle
- Carboxylic acid derivative
- Dialkyl ether
- Ether
- Amine
- Organic oxide
- Hydrocarbon derivative
- Organohalogen compound
- Organofluoride
- Organonitrogen compound
- Carbonyl group
- Organopnictogen compound
- Organic oxygen compound
- Organic nitrogen compound
- Organooxygen compound
- Aromatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aromatic heteromonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 1.44 g/L | Not Available | | LogP | 0.9 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 3.76 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 11.5234 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.68 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1663.0 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 225.7 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 145.5 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 169.3 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 62.4 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 342.4 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 440.7 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 72.7 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 913.5 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 354.1 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1317.8 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 299.2 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 315.3 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 338.9 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 136.5 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 20.1 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Linezolid,1TMS,isomer #1 | CC(=O)N(C[C@H]1CN(C2=CC=C(N3CCOCC3)C(F)=C2)C(=O)O1)[Si](C)(C)C | 2895.6 | Semi standard non polar | 33892256 | | Linezolid,1TMS,isomer #1 | CC(=O)N(C[C@H]1CN(C2=CC=C(N3CCOCC3)C(F)=C2)C(=O)O1)[Si](C)(C)C | 2681.9 | Standard non polar | 33892256 | | Linezolid,1TMS,isomer #1 | CC(=O)N(C[C@H]1CN(C2=CC=C(N3CCOCC3)C(F)=C2)C(=O)O1)[Si](C)(C)C | 3772.9 | Standard polar | 33892256 | | Linezolid,1TBDMS,isomer #1 | CC(=O)N(C[C@H]1CN(C2=CC=C(N3CCOCC3)C(F)=C2)C(=O)O1)[Si](C)(C)C(C)(C)C | 3100.3 | Semi standard non polar | 33892256 | | Linezolid,1TBDMS,isomer #1 | CC(=O)N(C[C@H]1CN(C2=CC=C(N3CCOCC3)C(F)=C2)C(=O)O1)[Si](C)(C)C(C)(C)C | 2941.0 | Standard non polar | 33892256 | | Linezolid,1TBDMS,isomer #1 | CC(=O)N(C[C@H]1CN(C2=CC=C(N3CCOCC3)C(F)=C2)C(=O)O1)[Si](C)(C)C(C)(C)C | 3835.4 | Standard polar | 33892256 |
|
|---|
| General References | - Park IN, Hong SB, Oh YM, Kim MN, Lim CM, Lee SD, Koh Y, Kim WS, Kim DS, Kim WD, Shim TS: Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother. 2006 Sep;58(3):701-4. Epub 2006 Jul 19. [PubMed:16857689 ]
- South African Electronic Package Inserts [Link]
|
|---|